Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
OTCMKTS:EKTAY

Elekta Q4 2026 Earnings Report

Elekta logo
$5.09 0.00 (0.00%)
As of 09/25/2026 01:10 PM Eastern
ProfileEarnings HistoryForecast

Elekta EPS Results

Actual EPS
$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$521.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elekta Announcement Details

Quarter
Q4 2026
Date
5/28/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Wednesday, November 25, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Earnings Headlines

Elekta Broadens Adaptive Radiotherapy Portfolio Across Modalities
September 27 at 12:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-broadens-adaptive-radiotherapy-portfolio-across-modalities?utm_source=marketbeat.com&utm_medium=referral
Insulet (NASDAQ:PODD) & Elekta (OTCMKTS:EKTAY) Critical Comparison
September 27 at 8:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055432
Should You Convert a Traditional IRA to a Roth After 60?
Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-free qualified withdrawals, and no lifetime required minimum distributions. The catch: converting triggers ordinary income tax in the year you convert, and the decision cannot be reversed. The right move depends on your income, tax bracket, and retirement timeline.tc pixel
 |  SmartAsset (Ad)
Elekta AGM Approves Dividend, Board Mandates and New Incentive Plan
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-agm-approves-dividend-board-mandates-and-new-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
Elekta AB earnings call: margins up, growth uneven
August 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/elekta-ab-earnings-call-margins-up-growth-uneven?utm_source=marketbeat.com&utm_medium=referral
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
August 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4940741-elekta-ab-publ-ektay-q1-2027-earnings-call-transcript
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software. Elekta also provides related services, support and upgrades for healthcare providers.

Founded in 1972 by neurosurgeon Lars Leksell, Elekta has grown into an international supplier serving hospitals, clinics and cancer centers across Europe, North and South America, Asia-Pacific, the Middle East and Africa. The company is headquartered in Stockholm, Sweden, and its shares trade on Nasdaq Stockholm under the symbol “EKTA”; its American depositary shares trade over the counter under the symbol “EKTAY.”

View Elekta Profile
Earnings Tools